<DOC>
	<DOCNO>NCT00663702</DOCNO>
	<brief_summary>The purpose study determine whether switch subcutaneous administration abatacept safe participant rheumatoid arthritis previously receive long-term therapy intravenous abatacept</brief_summary>
	<brief_title>Phase IIIB Switching From Intravenous Subcutaneous Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Recruitment 2 BristolMyers Squibb ( BMS ) study ( BMS IM101029 [ NCT00048581 ] BMS IM101102 [ NCT00048568 ] ) . Completion final quarterly dose visit NCT00048581 NCT00048568 follow : US Canadian participant : Day 1821 visit ; Taiwanese participant : Day 1905 visit ; Mexican participant : Day 1989 visit . Agreement participate BMS IM101185 ( NCT00663702 ) final quarterly dose visit NCT00048581 NCT00048568 study follow : US Canadian participant : Day 1821 visit ; Taiwanese participant : Day 1905 visit ; Mexican participant : Day 1989 visit . At time completion NCT00048581 NCT00048568 protocol , participant meet criterion require discontinuation . Drug stabilization requirement : Participants receive concomitant medication ( diseasemodifying antirheumatic drug , corticosteroid , nonsteroidal antiinflammatory drug ) time last quarterly dose visit NCT00048581 NCT00048568 require maintain stable dose level time sign consent end first 3 month ( Day 85 ) current study . Willingness selfinject study medication ( abatacept ) allow caregiver inject study medication . Willingness adhere study visit schedule comply protocol requirement . Male female ( nurse pregnant ) gender , least 18 year age . Women childbearing potential ( WOCBP ) must practice adequate contraceptive measure study 10 week last infusion study medication manner risk pregnancy minimize . WOCBP must negative serum urine pregnancy test result ( minimum sensitivity 25 IU/L equivalent unit human chorionic gonadotropin [ HCG ] ) within 48 hour prior start study medication . The following treatment therapy start final quarterly dose visit NCT00048581 NCT00048568 study : Any biologic ; immunoabsorption column ( Prosorba column ) ; mycophenolate mofetil ; cyclosporin A calcineurin inhibitor ; Dpenicillamine ; live vaccine within 3 month Day 1 schedule receive live vaccine course study Current symptom severe , progressive , uncontrolled renal , hepatic , hematologic , gastrointestinal , pulmonary , cardiac , neurologic , cerebral disease , concomitant medical condition , opinion Investigator , might place participation unacceptable risk study participation Any clinical laboratory test result consider abnormal within acceptable limit final quarterly dose visit NCT00048581 NCT00048568 . Screening laboratory test result NCT00663702 base Day 1821 visit NCT00048581 NCT00048568 participant enrol site US Canada Day 1989 visit NCT00048568 participant enrol site Mexico . Imprisonment involuntarily incarceration treatment either psychiatric physical ( eg , infectious disease ) illness Impairment , incapacitation , inability complete studyrelated assessment , illiteracy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>